MUC1 and breast carcinoma: These compelling outcomes suggest that Apt‐Td holds considerable promise as a nanoparticle platform for advancing breast cancer treatment.[88b] Furthermore, investigators proposed an innovative strategy involving 1–3 MUC1‐aptamer‐modified DNA tetrahedra for DOX delivery in breast cancer.